Disease Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CDKN2A loss Palbociclib chordoma sensitive detail...
CDKN2A loss Abemaciclib chordoma sensitive detail...
MLH1 negative Pembrolizumab chordoma sensitive detail...
MSH6 negative Pembrolizumab chordoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01407198 Phase I Nilotinib Nilotinib With Radiation for High Risk Chordoma Active, not recruiting USA 0
NCT02383498 Phase II GI-6301 The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma Completed USA 0
NCT02389244 Phase II Regorafenib A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Recruiting FRA 0
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Completed USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT02989636 Phase I Nivolumab Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma Active, not recruiting USA 0
NCT03083678 Phase II Afatinib Afatinib in Locally Advanced and Metastatic Chordoma Unknown status NLD | ITA | GBR 0
NCT03110744 Phase II Palbociclib CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) Completed DEU 0
NCT03173950 Phase II Nivolumab Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting USA 0
NCT03623854 Phase II Nivolumab + Relatlimab Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma Completed USA 0
NCT03647423 Phase Ib/II Aldoxorubicin + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Withdrawn USA 0
NCT03886311 Phase II Nivolumab + Talimogene laherparepvec + Trabectedin Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) Recruiting USA 0
NCT04134312 Phase I MVA-BN-Brachyury A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer Completed USA 0
NCT04246671 Phase Ib/II TAEK-VAC-HerBy Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer Active, not recruiting USA 0
NCT04416568 Phase II Ipilimumab + Nivolumab Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN 0
NCT04741438 Phase III Ipilimumab + Nivolumab Pazopanib Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) Recruiting FRA 0
NCT04965753 Phase I FHD-609 FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors Terminated USA | ITA | FRA | ESP 0
NCT05041127 Phase II Cetuximab Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma Recruiting USA 0
NCT05286801 Phase Ib/II Atezolizumab + Tiragolumab Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Recruiting USA | CAN | AUS 0
NCT05407441 Phase Ib/II Ipilimumab + Nivolumab + Tazemetostat Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Recruiting USA 0